Cardiovascular Complications of Diabetic Kidney Disease (original) (raw)

2. Shaw JE, Sicree R a, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 2010;87(1):4–14. [PubMed] [Google Scholar]

3. Kannel WB. Diabetes and Cardiovascular Disease. The Framingham Study. JAMA. 1979;241(19):2035. [PubMed] [Google Scholar]

4. Seshasai SRK, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N. Engl. J. Med. 2011;364(9):829–41. [PMC free article] [PubMed] [Google Scholar]

5. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332(7533):73–8. [PMC free article] [PubMed] [Google Scholar]

6. Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380(9854):1662–73. [PMC free article] [PubMed] [Google Scholar]

7. Chun BY, Dobson AJ, Heller RF. The impact of diabetes on survival among patients with first myocardial infarction. Diabetes Care. 1997;20(5):704–8. [PubMed] [Google Scholar]

8. Haffner S, Lehto S. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 1998;339(4):229–234. [PubMed] [Google Scholar]

9. Keith DS, Nichols G a, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch. Intern. Med. 2004;164(6):659–63. [PubMed] [Google Scholar]

10. Levey AS, Eckardt K, Tsukamato Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) Kidney Int. 2005;67:2089–2100. [PubMed] [Google Scholar]

11. Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007;72(3):247–59. [PubMed] [Google Scholar]

12. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038–47. [PubMed] [Google Scholar]

13. De Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305(24):2532–9. [PMC free article] [PubMed] [Google Scholar]

14. Eriksen BO, Ingebretsen OC. The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. Kidney Int. 2006;69(2):375–82. [PubMed] [Google Scholar]

15. Astor BC, Hallan SI, Miller ER, Yeung E, Coresh J. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am. J. Epidemiol. 2008;167(10):1226–34. [PubMed] [Google Scholar]

16. Bello AK, Hemmelgarn B, Lloyd A, et al. Associations among estimated glomerular filtration rate, proteinuria, and adverse cardiovascular outcomes. Clin. J. Am. Soc. Nephrol. 2011;6(6):1418–26. [PMC free article] [PubMed] [Google Scholar]

17. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004;351(13):1296–305. [PubMed] [Google Scholar]

18. Hemmelgarn BR, Manns BJ, Lloyd A, et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA. 2010;303(5):423–9. [PubMed] [Google Scholar]

19. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073–81. [PMC free article] [PubMed] [Google Scholar]

20. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108(17):2154–69. [PubMed] [Google Scholar]

21. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PWF, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291(7):844–50. [PubMed] [Google Scholar]

22. Brancati FL. Risk of End-stage Renal Disease in Diabetes Mellitus - A Prospective Cohort Study of Men Screened for MRFIT. JAMA. 1997;278(23):2069. [PubMed] [Google Scholar]

23. Garg AX, Kiberd B a, Clark WF, Haynes RB, Clase CM. Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. Kidney Int. 2002;61(6):2165–75. [PubMed] [Google Scholar]

24. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N. Engl. J. Med. 1984;310(6):356–60. [PubMed] [Google Scholar]

25. Boer I de, Katz R, Cao J. Cystatin C, albuminuria, and mortality among older adults with diabetes. Diabetes Care. 2009;32(10) [PMC free article] [PubMed] [Google Scholar]

26. Ninomiya T, Perkovic V, de Galan BE, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J. Am. Soc. Nephrol. 2009;20(8):1813–21. [PMC free article] [PubMed] [Google Scholar]

27. So WY, Kong APS, Ma RCW, et al. Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients. Diabetes Care. 2006;29(9):2046–52. [PubMed] [Google Scholar]

28. Perkovic V, Verdon C, Ninomiya T, et al. The relationship between proteinuria and coronary risk: a systematic review and meta-analysis. PLoS medicine. 2008;5(10):e207. [PMC free article] [PubMed] [Google Scholar]

29. Ninomiya T, Perkovic V, Verdon C, et al. Proteinuria and stroke: a meta-analysis of cohort studies. Am. J. Kidney Dis. 2009;53(3):417–25. [PubMed] [Google Scholar]

30. Groop PH, Thomas MC, Moran JL, et al. The presence and severit of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes. 2009;58(7):1651–8. [PMC free article] [PubMed] [Google Scholar]

31. Orchard TJ, Secrest a M, Miller RG, Costacou T. In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia. 2010;53(11):2312–9. [PMC free article] [PubMed] [Google Scholar]

32. Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J. Am. Soc. Nephrol. 2013;24(2):302–8. [PMC free article] [PubMed] [Google Scholar]

33. Longenecker JC, Coresh J, Powe NR, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J. Am. Soc. Nephrol. 2002;13(7):1918–27. [PubMed] [Google Scholar]

34. Kovesdy CP, Anderson JE. Reverse epidemiology in patients with chronic kidney disease who are not yet on dialysis. Semin. Dial. 2007;20(6):566–9. [PubMed] [Google Scholar]

35. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch. Intern. Med. 2008;168(4):397–403. [PubMed] [Google Scholar]

36. Guérin AP, Pannier B, Marchais SJ, London GM. Arterial structure and function in end-stage renal disease. Curr. Hypertens. Rep. 2008;10(2):107–11. [PubMed] [Google Scholar]

37. Collins AJ, Ma JZ, Ebben J. Impact of hematocrit on morbidity and mortality. Semin. Nephrol. 2000;20(4):345–9. [PubMed] [Google Scholar]

38. Briet M, Schiffrin EL. Aldosterone: effects on the kidney and cardiovascular system. Nat. Rev. Nephrol. 2010;6(5):261–73. [PubMed] [Google Scholar]

39. Weiner DE, Tighiouart H, Elsayed EF, et al. Inflammation and cardiovascular events in individuals with and without chronic kidney disease. Kidney Int. 2008;73(12):1406–12. [PMC free article] [PubMed] [Google Scholar]

40. Stehouwer CD a, Smulders YM. Microalbuminuria and risk for cardiovascular disease: Analysis of potential mechanisms. J. Am. Soc. Nephrol. 2006;17(8):2106–11. [PubMed] [Google Scholar]

41. Jalal DI, Chonchol M, Targher G. Disorders of hemostasis associated with chronic kidney disease. Semin. Thromb. Hemost. 2010;36(1):34–40. [PubMed] [Google Scholar]

42. Carr ME. Diabetes mellitus: a hypercoagulable state. J. Diabetes Complications. 2001;15(1):44–54. [PubMed] [Google Scholar]

43. Baber U, Bander J, Karajgikar R, et al. Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity. Thromb. Haemost. 2013;110(1):118–23. [PubMed] [Google Scholar]

44. Chonchol M, Whittle J, Desbien A, Orner MB, Petersen LA, Kressin NR. Chronic kidney disease is associated with angiographic coronary artery disease. Am. J. Nephrol. 2008;28(2):354–60. [PubMed] [Google Scholar]

45. Anavekar N. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N. Engl. J. Med. 2004;351:1285–1295. [PubMed] [Google Scholar]

46. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995;47(1):186–92. [PubMed] [Google Scholar]

47. Cerasola G, Nardi E, Palermo A, Mulè G, Cottone S. Epidemiology and pathophysiology of left ventricular abnormalities in chronic kidney disease: a review. J. Nephrol. 24(1):1–10. [PubMed] [Google Scholar]

48. Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 2005;353(3):238–48. [PubMed] [Google Scholar]

49. Pun PH, Smarz TR, Honeycutt EF, Shaw LK, Al-Khatib SM, Middleton JP. Chronic kidney disease is associated with increased risk of sudden cardiac death among patients with coronary artery disease. Kidney Int. 2009;76(6):652–8. [PMC free article] [PubMed] [Google Scholar]

50. Lee M, Saver JL, Chang K-H, Liao H-W, Chang S-C, Ovbiagele B. Low glomerular filtration rate and risk of stroke: meta-analysis. BMJ. 2010;341:c4249. [PMC free article] [PubMed] [Google Scholar]

51. Seliger SL, Gillen DL, Longstreth WT, Kestenbaum B, Stehman-Breen CO. Elevated risk of stroke among patients with end-stage renal disease. Kidney Int. 2003;64(2):603–9. [PubMed] [Google Scholar]

52. Wizemann V, Tong L, Satayathum S, et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int. 2010;77(12):1098–106. [PubMed] [Google Scholar]

53. Go AS, Fang MC, Udaltsova N, et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation. 2009;119(10):1363–9. [PMC free article] [PubMed] [Google Scholar]

54. Sozio SM, Armstrong PA, Coresh J, et al. Cerebrovascular disease incidence, characteristics, and outcomes in patients initiating dialysis: the choices for healthy outcomes in caring for ESRD (CHOICE) study. Am. J. Kidney Dis. 2009;54(3):468–77. [PMC free article] [PubMed] [Google Scholar]

55. Plantinga L, Tuot D, Powe N. Awareness of chronic kidney disease among patients and providers. Adv. Chronic Kidney Dis. 2010;17(3):225–236. [PMC free article] [PubMed] [Google Scholar]

56. Fox CS, Muntner P, Chen AY, et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation. 2010;121(3):357–65. [PMC free article] [PubMed] [Google Scholar]

57. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–13. [PubMed] [Google Scholar]

58. Turner R, Holman R, Stratton I, et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317(7160):703–13. [PMC free article] [PubMed] [Google Scholar]

59. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321(7258):412–9. [PMC free article] [PubMed] [Google Scholar]

60. James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) JAMA. 2013 in press; doi: 10.1001/jama.2013.284427. [PubMed] [Google Scholar]

61. Brenner B, Cooper M. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001;345(12):861–869. [PubMed] [Google Scholar]

62. Lewis E, Hunsicker L. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 2001;345(12):851–860. 60. [PubMed] [Google Scholar]

63. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 1993;329(20):1456–62. [PubMed] [Google Scholar]

64. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N. Engl. J. Med. 2013;369(20):1892–903. [PubMed] [Google Scholar]

65. Hirst J a, Taylor KS, Stevens RJ, et al. The impact of renin-angiotensin-aldosterone system inhibitors on Type 1 and Type 2 diabetic patients with and without early diabetic nephropathy. Kidney Int. 2012;81(7):674–83. [PubMed] [Google Scholar]

66. Reichard P, Nilsson BY, Rosenqvist U. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986. [PubMed] [Google Scholar]

67. Turner RC, Holman RR, Cull CA, et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–53. [PubMed] [Google Scholar]

68. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 2008;359(15):1577–89. [PubMed] [Google Scholar]

69. Patel A, MacMahon S, Chalmers J, Neal B. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2008:2560–72. [PubMed] [Google Scholar]

70. Wounds D. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N. Engl. J. Med. 2008:2545–2559. [PMC free article] [PubMed] [Google Scholar]

71. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 2009;360(2):129–39. [PubMed] [Google Scholar]

72. Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation. 2004;110(12):1557–63. [PubMed] [Google Scholar]

73. Colhoun HM, Betteridge DJ, Durrington PN, et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS) Am. J. Kidney Dis. 2009;54(5):810–9. [PubMed] [Google Scholar]

74. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181–92. [PMC free article] [PubMed] [Google Scholar]

75. Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 2009;360(14):1395–407. [PubMed] [Google Scholar]

76. Tonelli M, Wanner C, Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members Lipid Management in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2013 Clinical Practice Guideline. Ann Intern Med. 2014;160(3):182–189. [PubMed] [Google Scholar]

77. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013 in press. [Google Scholar]

78. Phisitkul K, Hegazy K, Chuahirun T, et al. Continued smoking exacerbates but cessation ameliorates progression of early type 2 diabetic nephropathy. Am. J. Med. Sci. 2008;335(4):284–91. [PubMed] [Google Scholar]

79. Suckling RJ, He FJ, Macgregor GA. Altered dietary salt intake for preventing and treating diabetic kidney disease. Cochrane Database Syst. Rev. 2010;8:12. [PubMed] [Google Scholar]

80. Nezu U, Kamiyama H, Kondo Y, Sakuma M, Morimoto T, Ueda S. Effect of low-protein diet on kidney function in diabetic nephropathy: meta-analysis of randomised controlled trials. BMJ open. 2013;3(5):1–11. [PMC free article] [PubMed] [Google Scholar]

81. Thomas MC, Moran J, Forsblom C, et al. The association between dietary sodium intake, ESRD, and all-cause mortality in patients with type 1 diabetes. Diabetes Care. 2011;34(4):861–6. [PMC free article] [PubMed] [Google Scholar]

82. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 2003;348(5):383–93. [PubMed] [Google Scholar]

83. Ezekowitz J, McAlister FA, Humphries KH, et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J. Am. Coll. Cardiol. 2004;44(8):1587–92. [PubMed] [Google Scholar]

84. McClellan WM, Langston RD, Presley R. Medicare patients with cardiovascular disease have a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease. J. Am. Soc. Nephrol. 2004;15(7):1912–9. [PubMed] [Google Scholar]

85. Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA. 2006;296(11):1377–84. [PubMed] [Google Scholar]

86. Herzog C a, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO) Kidney Int. 2011;80(6):572–86. [PubMed] [Google Scholar]